Form 4: Atea Pharma EVP Acquires Shares, New Options

Atea Pharmaceuticals' EVP and Chief Accounting Officer, Wayne Foster, reported the acquisition of common stock through RSU vesting and a new stock option grant.

Summary

• Wayne Foster, EVP, Chief Accounting Officer of Atea Pharmaceuticals, Inc. (AVIR), reported changes in beneficial ownership.
• Acquired 41,333 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Disposed of 12,132 shares of common stock at $4.24 per share to cover tax withholding obligations related to RSU vesting.
• Received a new grant of 108,000 stock options with an exercise price of $4.24 per share.
• The stock options will vest in 48 equal monthly installments starting January 31, 2026, and will be fully vested by January 31, 2030.
• Following these transactions, Foster beneficially owns 79,329 shares of common stock and 108,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation activities without indicating any specific positive or negative operational or financial performance.

Positives

• EVP and Chief Accounting Officer Wayne Foster acquired 41,333 shares of common stock through RSU vesting, increasing his direct ownership.
• A new grant of 108,000 stock options provides a long-term incentive for the executive, aligning his interests with shareholders.

Negatives

• 12,132 shares of common stock were disposed of at $4.24 per share to satisfy tax withholding obligations, representing a reduction in direct share ownership.

Future Outlook

This Form 4 primarily reports past transactions and vesting schedules for future options. It does not contain forward-looking statements or guidance on company performance.

Industry Context

StockSavvy.ai notes that routine executive compensation transactions, such as RSU vesting and new option grants, are common across the biotechnology and pharmaceutical sectors. These filings provide transparency into executive incentives but typically do not reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• This filing details standard executive compensation practices, including RSU vesting and stock option grants, which are common mechanisms used by publicly traded companies, particularly in the biotech industry, to attract, retain, and incentivize key personnel. No specific comparable companies or projects are mentioned in this transaction report.

Stakeholder Impact

• Shareholders: The grant of new stock options aligns executive incentives with shareholder value creation over the long term. The sale of shares for tax purposes is a common and expected event.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• The newly granted stock options will vest in 48 equal monthly installments following January 31, 2026, fully vesting by January 31, 2030.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Wayne Foster, Beneficial Ownership